Multinational pharmaceutical firms planning to introduce patent-protected medicines in the domestic market may find it difficult to price their products at will. 


<tr><td><p class='TableClas'></p><P class='TableClas'> <DIV CLASS=rightDiv><script language="JavaScript">
		google_ad_client = 'businessstandard';
		//google_ad_client = 'ca-businessstandard_js';
		google_ad_width = 200;
		google_ad_height = 200;
		google_ad_format = "200x200_as";
		google_ad_type = "text";
		google_ad_channel = "";
		//google_color_border = "FFFFFF";
		google_color_border = "F7F7F7";
		//google_color_bg = "FFFFFF";
		google_color_bg = "ffffff";
		//google_color_link = "639ACE";
		google_color_link = "0253B7";
		google_color_text = "000000";
		google_color_url = "D63431";
		//google_skip = adsenseSkip;
		</script> 
		<script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
		</script> </DIV><p class='TableClas'>A government committee is looking at going beyond mere economic considerations and recommend an essentiality-linked pricing structure, it is learnt. 
</p><p class='TableClas'>A government committee is looking at going beyond mere economic considerations and recommend an essentiality-linked pricing structure, it is learnt. 
</p><p class='TableClas'>The move may upset the industry

Drug firms in a fix over govt`s new pricing plan

Also Read

GoM to finalise pharma policy soon

Gujarat, Andhra clear first hurdle for petro hubs

50 research projects delayed

MNC drug firms in a fix over duty cut

Dragon eye on pharma sector

Explore News